Venitara Market Atlas
Market Ready
EU, US and selected MENA market-entry strategy
A senior regulatory expert compares the route, the evidence, and the reimbursement position in each market you are considering, and recommends an order.
Where this sits
01Pathway
Ready
02Market
ReadyYou are here
03Company
Ready
04Evidence
Ready
05Submission
Ready
06Revenue
Ready
Your file, growing. Each stage begins with the work already in it.
Available at any stage
When to use Market Ready
More than one market is in play and nobody has decided which comes first. The decision is usually made by whichever market someone mentioned most recently.
The order you launch in sets the evidence programme, and the evidence programme is most of the budget. Choosing the sequence after the evidence is commissioned means paying for some of it twice.
What you receive
The Market Sequence
The recommended launch order, market by market, with the route, the classification, and the evidence each one expects.
What it contains
The recommended order, and the reasoning behind it
The regulatory pathway per market
The evidence expectations per market, and where they differ
The reimbursement position per market
What the work covers
| Market | Route assessed |
|---|---|
| European Union | CE marking under MDR 2017/745 or IVDR 2017/746 |
| United Kingdom | UKCA, and the routes currently recognised |
| Switzerland | Swiss authorised representative and MedDO obligations |
| United States | 510(k) or De Novo under FDA 21 CFR 807 |
| Saudi Arabia | SFDA medical device marketing authorisation |
| United Arab Emirates | Ministry of Health and Prevention registration |
Who does the work, and against what
The comparison is made against each authority's own published requirements, market by market, rather than against a general view of how regulation works.
Venitara has worked in cooperation with ten to twelve Notified Bodies and delivered more than forty regulatory projects, across EU, US, and Gulf routes.
What you can do with the result
You launch in an order you chose, with the evidence for the first market funded and the second market's requirements already known.
You can also tell an investor when revenue starts and in which currency, which is a different question from when the certificate arrives.
The two levels for this product
Explore | Attest | |
|---|---|---|
| What you get | An indicative market comparison built from your own answers | The market sequence read by a named senior expert and attested |
| Human review | No expert review | Reviewed by a named senior regulatory expert |
| What it may claim | An indicative view of the routes available | That this sequence was ready for submission on the date it was read |
| The mark | A notice that no regulatory expert has read it | The Attestation seal, on the document |
The Venitara Attestation records that a named senior regulatory expert has reviewed this document against the Venitara rubric, confirming concordance with the applicable regulatory requirements and assessing it as ready for submission at a defined point in time. It is not a conformity assessment under Regulation (EU) 2017/745, regulatory approval, a Notified Body certificate, or a guarantee of approval.
Scope and limits
Three things this product does not do
Register your product in any market.
The sequence tells you the order and the requirements. The registrations themselves are separate work, and in most markets they are made in your name.
Guarantee a timeline in any market.
Review times sit with each authority and change.
Replace local regulatory advice where a market requires it.
Some markets require a locally established representative, and that is a role rather than a document.
Where this leads
Company Ready.
Most of what the sequence asks for has to be produced inside a quality system, and that comes next.
Revenue Ready.
Reimbursement is the half of market entry that decides whether anyone pays, and in most EU markets it can start before the certificate arrives.
Common questions
We only care about the EU. Is this still worth it?+
If one market is genuinely settled, this is not your product. It exists for the decision between markets.
Does this include the US?+
The comparison does. The FDA route is assessed alongside the others so the sequence is real. Preparing a 510(k) or De Novo submission is separate work, quoted before it begins.
What is in the MENA scope?+
Saudi Arabia and the United Arab Emirates. Both are assessed against the current requirements of their own authorities.
How current is this?+
Every route is checked against the authority's published position at the time of the review, and the sequence is dated.
Need an expert read before the technical file leaves your company?
If you are still working out where to begin, the free MedTech Compass takes about ten minutes.
Free · AI generated · 10 mins